LGALS9 and hematopoietic and lymphoid cell neoplasm: Interestingly, for hematological cancers (all of which are chronic lymphocytic leukemia studies), higher Gal-9 expression was associated with shorter PFS and time to treatment (TTT), indicating rapid disease progression (HR =  2.29, 95% CI =  1.26-4.16, p = 0.007) (I2 =  30%, p =  0.24).